{"title":"\u30d2\u30e8\u3001\u3055\u304f\u3089\u3001\u3075\u3086\u3053\u3078","url":"https://usotsukibakari-3.hatenablog.com/entry/e11d89b7ac883aaf710c28c98c3373ad","height":"190","provider_name":"Hatena Blog","description":"\u4ee5\u4e0b\u306e\u8ad6\u6587\u3092\u8aad\u3093\u3067\u304a\u304f\u3053\u3068\u3092\u3001\u304a\u3059\u3059\u3081\u3057\u307e\u3059\u3002\u3010\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u5165\u308a\u30ef\u30af\u30c1\u30f3\u3068\u81ea\u5df1\u514d\u75ab\u75be\u60a3\u306e\u30ea\u30b9\u30af\u306b\u3064\u3044\u3066\u3011Safety assessment of adjuvanted vaccines: Methodological considerationsFernanda Tavares Da Silva, Alberta Di Pasquale, Juan P Yarzabal, and Nathalie Gar \u0327conHuman Vaccines & Immunotherapeutics 11:7, 1814--1824; July 2015https://www.ncbi.nlm.nih.gov\u2026","provider_url":"https://hatena.blog","type":"rich","blog_url":"https://usotsukibakari-3.hatenablog.com/","image_url":null,"version":"1.0","blog_title":"YuHi \u306e\u96d1\u611f","width":"100%","author_name":"usotsukibakari_3","categories":["io302\u3068io302\u306e\u4ef2\u826f\u3057\u3055\u3093\u3078"],"author_url":"https://blog.hatena.ne.jp/usotsukibakari_3/","published":"2020-08-14 11:21:45","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fusotsukibakari-3.hatenablog.com%2Fentry%2Fe11d89b7ac883aaf710c28c98c3373ad\" title=\"\u30d2\u30e8\u3001\u3055\u304f\u3089\u3001\u3075\u3086\u3053\u3078 - YuHi \u306e\u96d1\u611f\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>"}